HCM HUTCHMED (China) Ltd
Price Chart
Executive Summary
HUTCHMED presented Phase III ESLIM-02 data for sovleplenib in wAIHA at EHA 2026, showing a 66% durable response rate vs 15% placebo (p<0.0001) with a favorable safety profile. The NDA for wAIHA was accepted with priority review by China's NMPA in April 2026, and a resubmitted NDA for ITP also received priority review in February 2026. These regulatory milestones and strong efficacy data de-risk the pipeline for a second indication beyond ITP, though no revenue or earnings figures are disclosed.
Actionable Insight
The strong Phase III data and dual priority review status for wAIHA and ITP NDAs significantly de-risk sovleplenib's regulatory path in China. Monitor NMPA approval decisions and potential label expansion globally, as HUTCHMED retains worldwide rights.
Key Facts
- Phase III ESLIM-02 met primary endpoint: durable response rate 66% sovleplenib vs 15% placebo (p<0.0001)
- Overall response rate 70% vs 22% (p<0.0001); rescue therapy use reduced to 16% vs 54% (p=0.0001)
- NDA for wAIHA accepted with priority review by NMPA in April 2026; Breakthrough Therapy Designation granted March 2026
- Resubmitted NDA for ITP also granted priority review by NMPA in February 2026
- No TEAE-related deaths or treatment discontinuations in sovleplenib arm; Grade 3 TEAEs 43% vs 59% placebo
- HUTCHMED retains all worldwide rights to sovleplenib
Financial Impact
No revenue or financial figures disclosed; potential peak sales for sovleplenib in wAIHA and ITP in China are not quantified in the filing
Risk Factors
- Regulatory approval in China is not guaranteed despite priority review
- Commercial adoption depends on pricing, reimbursement, and competition from existing steroids and rituximab
- Global expansion outside China would require additional clinical trials and regulatory submissions
Market Snapshot
Documents Analyzed
This report is based on 5 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 6-K Filing (Primary) | 0001648257-26-000039 |
| Document: hcm-20260612x6k.htm | 0001648257-26-000039 |
| Document: 0001648257-26-000039-index-headers.html | 0001648257-26-000039 |
| Document: 0001648257-26-000039-index.html | 0001648257-26-000039 |
| Document: 0001648257-26-000039.txt | 0001648257-26-000039 |
Track record builds as more directional reports settle.
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
|
Jun 12, 2026
1d ago
|
6-K
| $10.75 awaiting T+20 | awaiting T+20 | — | $10.96 (+1.95%) |
|
Jun 12, 2026
1d ago
|
Press Release
| $10.75 awaiting T+20 | awaiting T+20 | — | $10.96 (+1.95%) |
|
Apr 9, 2026
9w ago
|
Press Release
| $15.16 $13.43 | ▼ −11.41% | ▼ −18.98% | $10.96 (−27.70%) |
|
Mar 23, 2026
11w ago
|
Press Release
| $14.00 $14.87 | ▲ +6.21% | ▼ −1.21% | $10.96 (−21.71%) |
|
Mar 5, 2026
14w ago
|
Press Release
| $13.85 $15.42 | ▲ +11.34% | ▲ +15.12% | $10.96 (−20.87%) |
|
Mar 4, 2026
14w ago
|
Press Release
| $13.65 $15.14 | ▲ +10.96% | ▲ +15.37% | $10.96 (−19.68%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Try SecBot Free Coming soon: SecBot Pro with alerts, watchlists, and API access